NexgenRx Inc
NexgenRx Inc. administers, adjudicates, and pays drug, dental, and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers in Canada. The company offers NexSys claims management; NexAdmin plan administration; and NexPSPAssist patient support programs. It also provides ancillary services. NexgenRx Inc. was incorporated in 2003 and is headquarte… Read more
NexgenRx Inc (NEGXF) - Net Assets
Latest net assets as of June 2025: $8.09 Million USD
Based on the latest financial reports, NexgenRx Inc (NEGXF) has net assets worth $8.09 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($35.67 Million) and total liabilities ($27.59 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $8.09 Million |
| % of Total Assets | 22.67% |
| Annual Growth Rate | N/A |
| 5-Year Change | 37.77% |
| 10-Year Change | N/A |
| Growth Volatility | 497.47 |
NexgenRx Inc - Net Assets Trend (2005–2024)
This chart illustrates how NexgenRx Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for NexgenRx Inc (2005–2024)
The table below shows the annual net assets of NexgenRx Inc from 2005 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $7.62 Million | -1.18% |
| 2023-12-31 | $7.71 Million | -12.06% |
| 2022-12-31 | $8.77 Million | -10.35% |
| 2021-12-31 | $9.79 Million | +76.84% |
| 2020-12-31 | $5.53 Million | +192.67% |
| 2019-12-31 | $1.89 Million | +31.96% |
| 2018-12-31 | $1.43 Million | -8.49% |
| 2017-12-31 | $1.57 Million | +177.03% |
| 2016-12-31 | $565.27K | +1035.58% |
| 2015-12-31 | $-60.42K | +86.99% |
| 2014-12-31 | $-464.55K | -1161.85% |
| 2013-12-31 | $-36.81K | +95.06% |
| 2012-12-31 | $-745.11K | +45.21% |
| 2011-12-31 | $-1.36 Million | -7.48% |
| 2010-12-31 | $-1.27 Million | +57.69% |
| 2009-12-31 | $-2.99 Million | +31.65% |
| 2008-12-31 | $-4.38 Million | -64.31% |
| 2007-12-31 | $-2.66 Million | -1508.99% |
| 2006-12-31 | $189.00K | +103.48% |
| 2005-12-31 | $-5.42 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to NexgenRx Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 696320800.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.01 Million | 52.61% |
| Other Components | $6.04 Million | 79.24% |
| Total Equity | $7.62 Million | 100.00% |
NexgenRx Inc Competitors by Market Cap
The table below lists competitors of NexgenRx Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Fun Yours Technology Co Ltd
TWO:6482
|
$8.65 Million |
|
INNOVATEC S.P.A.
F:5JT
|
$8.66 Million |
|
Pulsenmore Ltd. Ordinary Shares
NASDAQ:PLSM
|
$8.66 Million |
|
Olidata S.p.A.
F:OL40
|
$8.66 Million |
|
Max Power Mining Corp.
PINK:MAXXF
|
$8.65 Million |
|
MBL Infrastructure Limited
NSE:MBLINFRA
|
$8.65 Million |
|
Sabre Gold Mines Corp
OTCQB:SGLDF
|
$8.65 Million |
|
WASHINGTON POST -B- - Dusseldorf Stock Exchang
DU:WPOB
|
$8.65 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NexgenRx Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 7,714,872 to 7,623,961, a change of -90,911 (-1.2%).
- Net income of 614,569 contributed positively to equity growth.
- Dividend payments of 908,195 reduced retained earnings.
- New share issuances of 187,500 increased equity.
- Other comprehensive income increased equity by 2,885,043.
- Other factors decreased equity by 2,869,828.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $614.57K | +8.06% |
| Dividends Paid | $908.20K | -11.91% |
| Share Issuances | $187.50K | +2.46% |
| Other Comprehensive Income | $2.89 Million | +37.84% |
| Other Changes | $-2.87 Million | -37.64% |
| Total Change | $- | -1.18% |
Book Value vs Market Value Analysis
This analysis compares NexgenRx Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.96x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $0.00 | $0.20 | x |
| 2013-12-31 | $0.00 | $0.20 | x |
| 2014-12-31 | $0.00 | $0.20 | x |
| 2015-12-31 | $0.00 | $0.20 | x |
| 2016-12-31 | $0.01 | $0.20 | x |
| 2017-12-31 | $0.03 | $0.20 | x |
| 2018-12-31 | $0.02 | $0.20 | x |
| 2019-12-31 | $0.03 | $0.20 | x |
| 2020-12-31 | $0.08 | $0.20 | x |
| 2021-12-31 | $0.13 | $0.20 | x |
| 2022-12-31 | $0.12 | $0.20 | x |
| 2023-12-31 | $0.11 | $0.20 | x |
| 2024-12-31 | $0.10 | $0.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NexgenRx Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.06%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.73%
- • Asset Turnover: 0.54x
- • Equity Multiplier: 4.00x
- Recent ROE (8.06%) is above the historical average (6.74%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 11.92% | 5.68x | 0.00x | $602.63K |
| 2013 | 0.00% | 12.40% | 3.46x | 0.00x | $576.97K |
| 2014 | 0.00% | -11.33% | 0.57x | 0.00x | $-364.54K |
| 2015 | 0.00% | -4.01% | 0.99x | 0.00x | $-181.80K |
| 2016 | 104.75% | 10.21% | 0.95x | 10.80x | $535.61K |
| 2017 | -40.55% | -11.09% | 0.74x | 4.93x | $-791.66K |
| 2018 | -48.48% | -10.02% | 0.53x | 9.21x | $-837.95K |
| 2019 | -11.30% | -2.23% | 0.44x | 11.51x | $-402.69K |
| 2020 | 38.32% | 20.36% | 0.41x | 4.57x | $1.57 Million |
| 2021 | 41.37% | 34.09% | 0.40x | 3.03x | $3.07 Million |
| 2022 | -0.25% | -0.18% | 0.49x | 2.91x | $-899.50K |
| 2023 | -4.30% | -2.40% | 0.46x | 3.91x | $-1.10 Million |
| 2024 | 8.06% | 3.73% | 0.54x | 4.00x | $-147.83K |
Industry Comparison
This section compares NexgenRx Inc's net assets metrics with peer companies in the Health Information Services industry.
Industry Context
- Industry: Health Information Services
- Average net assets among peers: $79,108,599
- Average return on equity (ROE) among peers: -247.59%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NexgenRx Inc (NEGXF) | $8.09 Million | 0.00% | 3.41x | $8.65 Million |
| Accolade, Inc. (ACCD) | $473.79 Million | -97.02% | 0.91x | $448.32 Million |
| Achiko AG (ACHKF) | $-4.58 Million | 0.00% | 0.00x | $314.42K |
| Ascom Holding AG (ACMLF) | $78.70 Million | 22.11% | 1.51x | $152.13 Million |
| Accelera Innovations Inc (ACNV) | $-462.52K | 0.00% | 0.00x | $5.72K |
| Aclarion Inc (ACON) | $-7.08 Million | 0.00% | 0.00x | $1.89 Million |
| Alternate Health Corp (AHGIF) | $1.07 Million | -2231.82% | 7.94x | $6.50K |
| AI/ML Innovations Inc (AIMLF) | $2.09 Million | -130.52% | 0.72x | $6.84 Million |
| NetraMark Holdings Inc. (AINMF) | $-198.56K | 0.00% | 0.00x | $70.13 Million |
| AMJ Global Technology (AMJT) | $-21.78K | 0.00% | 0.00x | $10.99 Million |
| American Well Corp (AMWL) | $247.79 Million | -38.62% | 0.31x | $78.62 Million |